Liquidia Technologies Inc faces a significant drop in stock value as investors react to recent developments and market conditions.
Liquidia Technologies Inc (NASDAQ:LQDA) experienced a downturn in its stock price, closing down 1.33% in today’s session. This decline comes despite the company’s recent advancements in the biopharmaceutical sector, including FDA designations and promising financial results.
Advertisement
Liquidia Technologies Inc
LQDA.US
LQDA.US
Liquidia Technologies Inc
WealthAwesomeMarket cap
$3.04B
P/E
24.4x
52W high
$93.61
52W low
$21.94
1W change
+27.21%
Beta
0.61
Analyst Price Targets
Based on 8 analysts covering LQDA · as of Oct 15, 2026
Wall Street analysts forecast LQDA stock price to rise 57.6% over the next 12 months.
Consensus
Buy3.75 / 5.00
Avg. Target
C$53.50
+57.6% Upside
Previously C$49.33 on Oct 12, 2026
Current Price
C$33.94
Last close
Analyst Breakdown (8 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LQDA's historical volatility
30-Day Vol
262.9%
Annualized
90-Day Vol
166.1%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$28.39
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$31.98 | C$12.91 – C$79.21 |
| 60 trading days | C$30.13 | C$8.35 – C$108.67 |
| 90 trading days | C$28.39 | C$5.90 – C$136.60 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should be cautious as Liquidia's stock faces pressure, potentially influenced by broader market trends and investor sentiment despite its recent achievements.
Stock down 1.33% today
Liquidia's market cap stands at approximately $5.99 billion, reflecting investor sentiment amidst the recent stock performance.
Bull case
Liquidia is making strides in treating respiratory diseases. The recent FDA Fast Track designation for YUTREPIA® could spark greater market interest and boost sales in the future.
Bear case
The recent stock decline raises concerns about market confidence in Liquidia’s growth trajectory, especially given the competitive landscape in the biopharmaceutical industry.
Market Reaction
Advertisement
Liquidia's stock price fell by 1.33% in today’s trading session, signaling a potential shift in investor confidence. The decline comes despite the company’s recent achievements, including the Fast Track designation for YUTREPIA®, which could have positioned it favorably in the market.
Recent Developments
While Liquidia has made progress with its product offerings and received recognition from the FDA, the stock's performance suggests that investors may be weighing these positives against broader market conditions and competition within the biopharmaceutical sector.
Looking Ahead
Investors will be closely monitoring Liquidia's upcoming announcements and market performance. The company's ability to capitalize on its recent FDA designation and maintain sales momentum will be crucial in restoring investor confidence and stabilizing stock performance.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
